e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Pneumonia in childhood: new perspectives
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum procalcitonin and community-acquired pneumonia in childhood
M. Don, F. Valent, E. Falleti, L. Fasoli, M. Canciani (Udine, Italy)
Source:
Annual Congress 2005 - Pneumonia in childhood: new perspectives
Session:
Pneumonia in childhood: new perspectives
Session type:
Thematic Poster Session
Number:
1094
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Don, F. Valent, E. Falleti, L. Fasoli, M. Canciani (Udine, Italy). Serum procalcitonin and community-acquired pneumonia in childhood. Eur Respir J 2005; 26: Suppl. 49, 1094
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006
Serum levels of IL-6 in severe community-acquired pneumonia
Source: Annual Congress 2010 - Pulmonary infections and sepsis
Year: 2010
C-reactive protein in community-acquired pneumonia
Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia
Year: 2006
Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008
Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
The influence of prednisolone on C-reactive protein and procalcitonin in patients hospitalised with community-acquired pneumonia
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010
Serum procalcitonin in pneumococcal pneumonia in children
Source: Eur Respir J 2001; 17: 623-627
Year: 2001
Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia
Source: Eur Respir J 2008; 31: 356-362
Year: 2008
Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008
Serum procalcitonin concentrations in children with pulmonary tuberculosis, tuberculous infection and lober pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 176s
Year: 2003
Serum indicators for the diagnosis of pneumocystis pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 559s
Year: 2006
Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Usefulness of serum cortisol in assessment for the severity of community-acquired pneumonia
Source: Annual Congress 2011 - Assessment of severity and predictors of outcomes in community-acquired pneumonia
Year: 2011
Procalcitonin has wider applicability in community-acquired pneumonia than other biomarkers
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Serum KL-6 elevation related with severity in patients with pneumocystis pneumonia
Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies
Year: 2011
Usefullness of CPR and PCT in the etiological diagnosis of community-acquired pneumonia
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Predictive value of procalcitonin in ventilator-associated pneumonia
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007
Serum KL-6 level is increased in patients with
pneumocystis
pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 101s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept